Loading organizations...
§ Private Profile · Chengdu, Sichuan, China
A global commercial-stage biotechnology company developing vaccines and biologic therapeutic candidates for global health.
Clover Biopharmaceuticals is a global commercial-stage biotechnology company developing innovative vaccines and biologic therapeutic candidates, with principal operations based in Chengdu and Shanghai, China. The publicly traded firm integrates internal research, clinical development, and large-scale manufacturing capabilities to produce specialized treatments addressing critical global health needs. Trading on the Hong Kong Stock Exchange under the ticker 2007, the enterprise successfully raised $240 million during its initial public offering in November 2021. The company has received early financial backing from prominent figures including Bill Gates, while its board of directors features medical industry veterans such as Donna Ambrosino and Ralf Clemens. Currently led by Chief Executive Officer Joshua Liang, the organization maintains a diverse pipeline of proprietary biologic therapies alongside its fully commercialized vaccine products. Clover Biopharmaceuticals was originally founded in 2007 by Peng Liang.
Clover Biopharmaceuticals has raised $306.8M across 4 funding rounds.
Clover Biopharmaceuticals has raised $306.8M in total across 4 funding rounds.
Clover Biopharmaceuticals has raised $306.8M in total across 4 funding rounds.
Clover Biopharmaceuticals's investors include Temasek Holdings, Tim Xiao, Guangyu Xu, Tianhe Life Sciences.
Clover Biopharmaceuticals has raised $306.8M across 4 funding rounds. Most recently, it raised $230.0M Series C in February 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 23, 2021 | $230M Series C | Temasek Holdings | — | Announced |
| Jun 8, 2020 | $24M Series B | — | — | Announced |
| Nov 28, 2019 | $43.3M Series B | TIM Xiao, Guangyu XU | — | Announced |
| Dec 14, 2017 | $9.5M Series A | Tianhe Life Sciences | — | Announced |